The sponsor of the investigational ophthalmic bevacizumab drug, Ipique, that the European Medicines Agency last year said should not be granted pan-EU marketing approval for treating age-related macular degeneration (AMD) has asked the agency to re-examine its negative recommendation.
If the EMA changes its mind after the re-examination, Ipique could become the first drug containing bevacizumab to be
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?